Clinical trials
Terminated Cholangiocarcinoma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
97 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 4 |
| 2008 | 1 |
| 2009 | 4 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 9 |
| 2015 | 6 |
| 2016 | 4 |
| 2017 | 7 |
| 2018 | 2 |
| 2019 | 9 |
| 2020 | 8 |
| 2021 | 9 |
| 2022 | 13 |
| 2023 | 2 |
| 2024 | 5 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 97 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Mayo Clinic | 4 |
| Incyte Corporation | 3 |
| M.D. Anderson Cancer Center | 3 |
| Stanford University | 3 |
| Weill Medical College of Cornell University | 3 |
| Alaunos Therapeutics | 2 |
| Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2 |
| Medical University of South Carolina | 2 |
| QED Therapeutics, a BridgeBio company | 2 |
| University of Utah | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cholangiocarcinoma | 97 |
| Biliary Tract Neoplasms | 16 |
| Colorectal Neoplasms | 15 |
| Gallbladder Neoplasms | 14 |
| Pancreatic Neoplasms | 14 |
| Carcinoma, Hepatocellular | 13 |
| Bile Duct Neoplasms | 12 |
| Carcinoma, Non-Small-Cell Lung | 10 |
| Ovarian Neoplasms | 10 |
| Esophageal Neoplasms | 9 |
Trials
Showing 1 to 25 of 97. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.